SG11202001115TA - Combination therapy for treating cancer with an intravenous administration of a recombinant mva and an antibody - Google Patents
Combination therapy for treating cancer with an intravenous administration of a recombinant mva and an antibodyInfo
- Publication number
- SG11202001115TA SG11202001115TA SG11202001115TA SG11202001115TA SG11202001115TA SG 11202001115T A SG11202001115T A SG 11202001115TA SG 11202001115T A SG11202001115T A SG 11202001115TA SG 11202001115T A SG11202001115T A SG 11202001115TA SG 11202001115T A SG11202001115T A SG 11202001115TA
- Authority
- SG
- Singapore
- Prior art keywords
- antibody
- combination therapy
- treating cancer
- intravenous administration
- recombinant mva
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 238000002648 combination therapy Methods 0.000 title 1
- 238000001990 intravenous administration Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001152—Transcription factors, e.g. SOX or c-MYC
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
- A61K39/285—Vaccinia virus or variola virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6075—Viral proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Virology (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17187824 | 2017-08-24 | ||
| PCT/EP2018/072789 WO2019038388A1 (fr) | 2017-08-24 | 2018-08-23 | Polythérapie pour le traitement du cancer par administration intraveineuse d'un mva de recombinaison et d'un anticorps |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202001115TA true SG11202001115TA (en) | 2020-03-30 |
Family
ID=59702586
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202001115TA SG11202001115TA (en) | 2017-08-24 | 2018-08-23 | Combination therapy for treating cancer with an intravenous administration of a recombinant mva and an antibody |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11273211B2 (fr) |
| EP (1) | EP3691675A1 (fr) |
| JP (1) | JP7202362B2 (fr) |
| KR (1) | KR20200044000A (fr) |
| CN (1) | CN111050790B (fr) |
| AU (1) | AU2018320417A1 (fr) |
| BR (1) | BR112020003669A2 (fr) |
| CA (1) | CA3073310A1 (fr) |
| IL (1) | IL272546B2 (fr) |
| MX (1) | MX2020001856A (fr) |
| SG (1) | SG11202001115TA (fr) |
| WO (1) | WO2019038388A1 (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020207641A1 (en) | 2019-01-10 | 2021-07-22 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| PE20221182A1 (es) | 2019-11-18 | 2022-08-05 | Janssen Biotech Inc | Vacunas basadas en calr y jak2 mutantes y sus usos |
| WO2021263081A2 (fr) * | 2020-06-26 | 2021-12-30 | National Breast Cancer Coalition | Vaccin contre le cancer du sein |
| WO2022192268A1 (fr) * | 2021-03-10 | 2022-09-15 | University Of Iowa Research Foundation | Procédés d'amélioration de thérapies à base d'anticorps |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5766598A (en) | 1991-03-07 | 1998-06-16 | Virogenetics Corporation | Recombinant attenuated ALVAC canarypoxvirus expression vectors containing heterologous DNA segments encoding lentiviral gene products |
| JP4475683B2 (ja) | 1996-07-25 | 2010-06-09 | アメリカ合衆国 | 腫瘍関連抗原に対する免疫のための組換えポックス・ウイルス |
| EP1865065A1 (fr) * | 1998-12-09 | 2007-12-12 | The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services | Vecteur recombinant exprimant plusieurs molécules costimulantes et ses utilisations |
| CZ295808B6 (cs) | 2000-11-23 | 2005-11-16 | Bavarian Nordic A/S | Modifikovaný virus vakcinie typu Ankara |
| DK1461073T3 (da) | 2001-11-30 | 2010-03-29 | Us Gov Health & Human Serv | Peptidagonister til prostataspecifikt antigen og anvendelser heraf |
| CA2466413C (fr) | 2001-12-04 | 2014-11-04 | Bavarian Nordic A/S | Vaccin a sous-unite de ns1 de flavivirus |
| CA2532460C (fr) * | 2003-07-21 | 2012-04-24 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Gene synthetique codant l'antigene du facteur de croissance epidermique humain 2/neu et utilisations de celui-ci |
| JP2012509678A (ja) | 2008-11-27 | 2012-04-26 | バヴァリアン・ノルディック・アクティーゼルスカブ | 組換えウイルス発現のためのプロモーター |
| US8394385B2 (en) | 2009-03-13 | 2013-03-12 | Bavarian Nordic A/S | Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines |
| US10383924B2 (en) | 2009-04-17 | 2019-08-20 | Globeimmune, Inc. | Combination immunotherapy compositions against cancer and methods |
| US10111946B2 (en) | 2012-06-22 | 2018-10-30 | Bavarian Nordic A/S | Poxviral vectors for low antibody response after a first priming immunization |
| US10973892B2 (en) * | 2012-09-04 | 2021-04-13 | Bavarian Nordic A/S | Methods and compositions for enhancing vaccine immune responses |
| WO2014043535A1 (fr) * | 2012-09-14 | 2014-03-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compositions destinées à traiter le cancer |
| EP2895191B1 (fr) * | 2012-09-14 | 2019-06-05 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Protéine brachyury, vecteurs adénoviraux codant pour la protéine brachyury, et leur utilisation |
| WO2014062778A1 (fr) | 2012-10-19 | 2014-04-24 | Bavarian Nordic, Inc. | Méthodes et compositions pour le traitement du cancer |
| WO2014063832A1 (fr) | 2012-10-28 | 2014-05-01 | Bavarian Nordig A/S | Promoteur pr13.5 pour lymphocytes t robustes et réponses d'anticorps |
| US9725494B2 (en) * | 2013-05-17 | 2017-08-08 | United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Soluble CD27 (sCD27) and the use thereof |
| AU2014347004B2 (en) * | 2013-11-05 | 2019-08-08 | Bavarian Nordic A/S | Combination therapy for treating cancer with a poxvirus expressing a tumor antigen and an antagonist and/or agonist of an immune checkpoint inhibitor |
| CN105829537B (zh) * | 2013-11-28 | 2020-09-22 | 巴法里安诺迪克有限公司 | 用于使用痘病毒载体诱导增强的免疫应答的组合物和方法载体 |
| DK3142690T3 (da) * | 2014-05-13 | 2022-05-09 | Bavarian Nordic As | Kombinationsterapi til behandling af cancer med et rekombinant poxvirus, der eksprimerer et tumorantigen, og en immun-checkpointmolekyleantagonist eller -agonist |
| US20170196953A1 (en) | 2014-07-07 | 2017-07-13 | Duke University | VACCINES AGAINST AN ONCOGENIC ISOFORM OF HER2 (ErbB2) AND METHODS OF USING THE SAME |
| US10512684B2 (en) * | 2014-09-26 | 2019-12-24 | Bavarian Nordic A/S | Methods and compositions for intra-nasal immunization with recombinant MVA encoding flagellin |
| JP6851364B2 (ja) | 2015-07-31 | 2021-03-31 | バヴァリアン・ノルディック・アクティーゼルスカブ | ポックスウイルスにおける発現を増強するためのプロモーター |
| US20220000997A1 (en) * | 2019-02-19 | 2022-01-06 | Bavarian Nordic A/S | Therapy for Treating Cancer with an Intratumoral or Intravenous Administration of a Recombinant MVA Encoding 4-1BBL (CD137L) and/or CD40L |
| MX2022005601A (es) * | 2019-11-20 | 2022-08-15 | Bavarian Nordic As | Usos médicos de virus vaccinia ankara modificado (mva) recombinante con adyuvante de ligando de 4-1bb (4-1bbl). |
| WO2023118508A1 (fr) * | 2021-12-23 | 2023-06-29 | Bavarian Nordic A/S | Virus mva recombinants pour administration intrapéritonéale pour le traitement du cancer |
-
2018
- 2018-08-23 CN CN201880054776.8A patent/CN111050790B/zh active Active
- 2018-08-23 SG SG11202001115TA patent/SG11202001115TA/en unknown
- 2018-08-23 KR KR1020207005076A patent/KR20200044000A/ko not_active Application Discontinuation
- 2018-08-23 EP EP18756447.1A patent/EP3691675A1/fr active Pending
- 2018-08-23 US US16/641,236 patent/US11273211B2/en active Active
- 2018-08-23 MX MX2020001856A patent/MX2020001856A/es unknown
- 2018-08-23 IL IL272546A patent/IL272546B2/en unknown
- 2018-08-23 WO PCT/EP2018/072789 patent/WO2019038388A1/fr unknown
- 2018-08-23 CA CA3073310A patent/CA3073310A1/fr active Pending
- 2018-08-23 AU AU2018320417A patent/AU2018320417A1/en active Pending
- 2018-08-23 BR BR112020003669-2A patent/BR112020003669A2/pt unknown
- 2018-08-23 JP JP2020511314A patent/JP7202362B2/ja active Active
-
2022
- 2022-03-14 US US17/693,716 patent/US11723964B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN111050790A (zh) | 2020-04-21 |
| US20200306352A1 (en) | 2020-10-01 |
| US11273211B2 (en) | 2022-03-15 |
| EP3691675A1 (fr) | 2020-08-12 |
| IL272546A (en) | 2020-03-31 |
| US20220249636A1 (en) | 2022-08-11 |
| JP2020531524A (ja) | 2020-11-05 |
| CN111050790B (zh) | 2024-07-12 |
| US11723964B2 (en) | 2023-08-15 |
| CA3073310A1 (fr) | 2019-02-28 |
| IL272546B1 (en) | 2023-09-01 |
| BR112020003669A2 (pt) | 2020-09-01 |
| RU2020111588A (ru) | 2021-09-24 |
| AU2018320417A1 (en) | 2020-02-27 |
| MX2020001856A (es) | 2020-07-13 |
| JP7202362B2 (ja) | 2023-01-11 |
| IL272546B2 (en) | 2024-01-01 |
| RU2020111588A3 (fr) | 2022-03-29 |
| KR20200044000A (ko) | 2020-04-28 |
| WO2019038388A1 (fr) | 2019-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL272546B1 (en) | Combined therapy for the treatment of cancer with intravenous administration of recombinant mva and antibody | |
| IL297418B1 (en) | Combined immunotherapy and cytokine control therapy for cancer treatment | |
| IL261008A (en) | Combined immunotherapy and cytokine control therapy for cancer treatment | |
| IL283838A (en) | A method of treating cancer by combined treatment | |
| IL272740A (en) | Combined immunotherapy and cytokine control therapy for cancer treatment | |
| IL272636A (en) | Drug delivery device with combination assembly and related assembly method | |
| HK1256269A1 (zh) | 溴區結構域抑制劑和檢查點阻斷的組合療法 | |
| IL248507A0 (en) | Combined therapy for the treatment of cancer with a recombinant focovirus that expresses an antigen and an antagonist or agonist for an immune control molecule | |
| MX2016005980A (es) | Terapia de combinación para el cáncer usando inhibidores de la proteína bromodominio y extra-terminal. | |
| MX2016002645A (es) | Tratamiento combinado para tratar el glioblastoma. | |
| IL283187A (en) | Therapy for the treatment of cancer with intratumoral and/or intravenous administration of recombinant MVA encoding 4-1BBL (CD137L) and/or CD40L | |
| IL281988A (en) | Combination therapy for the treatment of cancer with intravenous administration of recombinant MVA and an immune checkpoint antagonist or agonist | |
| IL248704A0 (en) | Combined treatment with immunotherapy and radiotherapy for the treatment of cancers that express her-2 | |
| IL275550A (en) | Recombinant virus on a region reduced from optimal for a codon pair and its use for cancer treatment | |
| IL275940A (en) | Combined treatment with antibodies against IL-8 and against PD-1 for cancer treatment | |
| MX2023008849A (es) | Terapia combinada mediante el uso de un conjugado de anticuerpo-farmaco de liv1 (liv1-adc) y agente quimioterapeutico. | |
| IL282007A (en) | Medicine to treat chronic cough | |
| EP3888648A4 (fr) | Traitement du cancer par combinaison d'inhibiteur de point de contrôle immunitaire et de thérapie par folfirinox | |
| HK1257239A1 (zh) | 預防和治療肥胖症的藥物及其用途 | |
| SG11202005296SA (en) | Combination therapy between anti-progastrin antibody and immunotherapy to treat cancer | |
| HK1257584A1 (zh) | 預防和治療系統性硬化症的藥物及其用途 | |
| IL304245A (en) | Phospholipid-flaveglin conjugates and methods of using them for targeted cancer treatment | |
| EP3421039A4 (fr) | Médicament pour le traitement du cancer caractérisé par l'administration d'une association d'un inhibiteur de l'axl et d'un inhibiteur de point de contrôle immunitaire | |
| EP3549608A4 (fr) | Utilisation d'une association d'inhibiteur de vegfr et d'inhibiteur de parp dans la préparation d'un médicament pour le traitement d'un cancer gastrique | |
| IL288178A (en) | Combined gmci and ddri treatment for cancer |